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ALLOGRAFTING IN PATIENTS WITH SEVERE, REFRACTORY APLASTIC
ANEMIA USING PERIPHERAL BLOOD STEM CELLS AND A FLUDARA-
BINE-BASED CONDITIONING REGIMEN: THE MEXICAN EXPERIENCE
Gomez-Almaguer, D.1; Vela-Ojeda, J.2; Jaime-Perez, J.C.1; Gutier-
rez-Aguirre, C.H.1; Cantu-Rodriguez, O.G.1; Sobrevilla-Calvo, P.3;
Rivas-Vera, S.3; Gomez-Rangel, J.D.4; Ruiz-Arguelles, G.J.4 1. Hos-
pital Universitario, Monterrey, Nuevo Leon, Mexico; 2. Centro Medico
la Raza, Mexico City, Mexico; 3. Instituto Nacional de Cancerologia,
Mexico City, Mexico; 4. Centro de Hematologia y Medicina Interna,
Puebla, Mexico.
We studied the effectiveness of a ﬂudarabine/cyclophosphamide-
based conditioning regimen without anti-thymocyte globulin in 23
aplastic anemia patients, who had no response to previous conven-
tional pharmacologic treatment. Patients received oral busulphan 4
mg/kg/day/2 days, IV cyclophosphamide 350 mg/m2/day/3 days
and ﬂudarabine 30 mg/m2/day/3 days. For GVHD prophylaxis
patients received MTX 5 mg/m2 days 1, 3, 6, and 11 and oral
cyclosporin-A (CyA) 5 mg/kg/day, starting on day 1. Peripheral
blood stem cell products were used with a median dose of 5.5 106
CD34/kg. The patients were followed for an average of 25
months. By a median of day 11 an ANC 0.5  109/L was
reached; and by day, 12 the platelet count had reached
20,000  109/L. Acute grade I-II GVHD occurred in 4 patients,
whereas limited chronic GVHD presented in 6 cases. Twenty one
patients (91.3%) achieved engraftment. Two patients failed to
engraft and 4 developed late rejection, two of these individuals
died, 2 survive with high transfusion requirements, whereas 2
received a second peripheral blood stem cell infusion and achieved
sustained engraftment. Currently 21 (91%) of the 23 patients are
alive, whereas 19 of 21 (90%) remain in complete remission. The
average cost was about ﬁfteen thousand US dollars for this kind of
non-myeloablative transplant. Non-myeloablative stem cell trans-
plantation represents an affordable alternative to traditional more
cytotoxic conditioning for severe aplastic anemia (SAA) patients.
Long-term effects however, remain to be evaluated.
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ONE YEAR FOLLOW UP OF 71 LEUKEMIC PATIENTS WHO RECEIVED
FLUDARABINE AND BUSULFAN (FLUBUP) AS MYELOABLATIVE CONDI-
TIONING REGIMEN FOR ALLOGENEIC PBSCT
Iravani, M.; Tavakoli, M.; Shamshiri, A.R.; Mousavi, A.; Bahar, B.;
Ghavamzadeh, A. Hematology-Oncology and BMT research Center,
Tehran University of Medical Science, Tehran, Islamic Republic of Iran.
We are evaluating ﬂudarabine (40 mg/m2 on days 6 to 2) and
busulfan (4 mg/kg/day on days 5 to 2) as a new conditioning
regimen for allogeneic peripheral blood stem cell transplantation
in leukemic patients with matched related donors. Seventy one
patients were enrolled, 18 with high and 53 with standard risk (18
ALL, 35 AML, 16 CML and 2 MDS; F29 M42). The median
patient age was 23.7 years (range, 2.4–46.7). Cyclosporine was
used as a prophylactic agent for GVHD (3 mg/kg IV till 4, 10
mg/kg oral from day 5). The median follow-up was one year
(range, 50–592 days). 91.5% and 15.5% developed mucositis and
hepatic toxicity respectively which resolved with conservative ther-
apy. There was no cardiac toxicity (except one patient with mild
pericardial effusion and another with tachycardia). The median of
highest serum creatinine level during hospitalization were 1.6
mg/dl (range, 0.8–3.7; 24.3% with Cr 2) and serum cyclosporine
level, at the same time, was 246 ng/ml (range, 9–814). 7% expe-
rienced hemorrhagic cystitis (infection was ruled out) and 36.6%
experienced moderate to severe headache. 38% and 14.1% of the
patients showed grade 1, 2 and grade 3 acute GVHD respectively.
Grade 4 acute GVHD was found in one patient. 50% and 7%
showed limited and extensive chronic GVHD. 27% of patients
became CMV (min 17, max 69). The median times for neu-
trophil and platelet recovery were 10 (min 0, max26) and 12 (min
0, max 30) days. In day 38, 86.7% of the patients had 90% or
more, mononuclear chimerism (with STR-PCR technique; me-
dian, 97%; range, 25–100). 5 ALL and 8 AML patients relapsed
(18.3% of all patients, post transplantation lymphoproliferative
disease was found in one of them) and 8 (11%) died after relapse.
Nonrelapse mortality was 15.5% (11 patients; acute GVHD grade
IV1, CMV infection and GVHD2, CMV infection2, pneu-
monia2, infection2, chronic GVHD2). With a median follow
up of one year (range, 1.6–20 months), the probability of overall
survival and disease free survival was 73% and 66% respectively. It
could be beneﬁcial to use ﬂudarabine versus cyclophosphamide in
standard conditioning regimen for leukemic patients because of
reduced toxicity, low incidence of acute GVHD and facilitated
donor engraftment.
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ALLOGENEIC BONE MARROW TRANSPLANTATION IN -THALAS-
SAEMIA—SINGLE CENTER STUDY
Hashmi, K.U.; Raza, S.; Khattak, B.K.; Ahmed, P.; Hussain, I. Armed
Forces Bone Marrow Transplant Center, Rawalpindi, Punjab, Pakistan.
Objective: To evaluate outcome of allogeneic BMT in -thalas-
saemia at Armed Forces Bone Marrow Transplant Center, Paki-
stan. Methods: Twenty-ﬁve patients with -thalassaemia under-
went allogeneic BMT/PBSC transplantation from HLA identical
sibling donors. Patients were classiﬁed in three groups according to
Pesaro (Italy) risk classiﬁcation. Class-I (n12) and Class-II (n8)
patients received conditioning with Bu14/Cy200, whereas Class-
III (n5) patients received conditioning with hydroxyurea, aza-
thioprine, ﬂudarabine, along with Bu14/Cy200. Cyclosporine,
prednisolone and methotrexate were given for GvHD prophylaxis.
Stem cells dose infused was 4.0  108/kg body weight of the
patient. Results: Since August 2001 till September 2004 a total of
25 patients suffering from -thalassaemia major underwent allo-
geneic bone marrow transplantation. Out of these 20 were males
and 5 females (male:female ratio 4:1). Ages ranged between 9
months to 14 years (median age: 4.64 years). Twelve patients were
in risk class-I, whereas 8 patients in class-II and 5 patients were in
risk class-III. Engraftment was seen in all the patients. Median time
to neutrophil recovery (ANC 0.5  109/l) was 13 days and
platelet recovery (20  109/l) was 15 days. Secondary graft
rejection was observed in 5 patients (20%) between 2–4 months
post transplant. Three patients were subjected to 2nd transplant,
out of these 2 achieved successful engraftment whereas 1 again
reverted back to -thalassaemia, whereas 1 died of VOD liver.
Acute GvHD was observed in 15 patients (60%). Grade-I acute
GvHD was seen in 09 patients (36%), Grade-II GvHD in 2
patients (8%), grade-III GvHD in 3 patients (12%) and grade-IV
GvHD in 1 patient (4%). Other common non infective complica-
tions were hypertension (n5) 20%, ﬁts (n3) 12%, VOD liver
(n2) 8%, haemorrhagic cyctic (n2) 8%. Major post transplant
infective complications were disseminated CMV infection (n2)
8%, pseudomonas septicemia (n1) 4%, disseminated tuberculosis
(n1) 4%. Overall mortality in all risk classes was 28% (n7).
Overall survival was (n18) 72%. Class wise survival was (10/12)
83.33% in Class-I, class-II (5/8) 62.5% and in Class-III (3/5) 60%.
Conclusion: Allogeneic BMT is the only curative therapy for
-thalassaemia patients, however the success rate can be increased if
the patients are selected carefully and transplanted at an early age.
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FACILITATING CELL (FC)-MEDIATED ALLOENGRAFTMENT OCCURS IN
THE CONTEXT OF IN VIVO REGULATORY T-CELL INDUCTION
Shinde Patil, V.R.; Colson, Y.L. Brigham and Women’s Hospital &
Harvard Medical School, Boston, MA.
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